Study on the Effect of Coenzyme Q10 Intervention on Cardiac Toxicity Induced by Osimertinib

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600117424

Enrollment

Unknown

Registered

2026-01-23

Start date

2026-01-30

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease caused by coenzyme Q10 in patients with non-small cell lung cancer

Interventions

ARB drugs group:N/A

ARB drugs + Coenzyme Q10 Group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients aged >=18 years with clinically diagnosed NSCLC; 2.Maintenance therapy with osimertinib monotherapy for NSCLC, with no concomitant use of other NSCLC treatments during maintenance therapy, including targeted therapies, immunotherapies, and chemotherapy agents. 3.Cardiac toxicity manifestations occurring during osimertinib treatment include QT interval prolongation, left ventricular dysfunction, abnormal cardiac function laboratory parameters, heart failure, pericardial effusion, etc. 4.Clinical Management of Cardiac Toxicity Induced by Osimertinib;

Exclusion criteria

Exclusion criteria: 1.The patient had pre-existing heart conditions prior to treatment with Osimertinib, including congenital heart disease and acquired heart disease. 2.Clinical data documentation is incomplete;

Design outcomes

Primary

Measure	Time frame
The reduction in NT-proBNP before and after treatment in the two groups;	—

Countries

China

Contacts

Public ContactZiye Zhou

The First Affiliated Hospital of Wenzhou Medical University

redd88@163.com+86 577 5555 9593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026